A randomized, double-blind, placebo, and active comparator-controlled, parallel-group study of the efficacy and safety of rivoglitazone as monotherapy treatment of type 2 diabetes mellitus

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 18 Sep 2021

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

26 May 2021 Biomarkers information updated
06 Nov 2012 Planned number of patients changed from 2600 to 2890 as reported by European Clinical Trials Database.
06 May 2008 Status changed from recruiting to terminated (DSPD focussing on Study 301 to confirm clinical profile before proceeding) as reported by ClinicalTrials.gov

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com